Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

NCT ID: NCT01393639

Last Updated: 2024-09-04

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

323 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-27

Study Completion Date

2014-06-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the safety and efficacy of multiple doses of PF-04171327, an experimental glucocorticoid drug, to prednisone at 5 mg or 10 mg and placebo in the treatment of rheumatoid arthritis. All subjects will also be receiving background treatment of methotrexate for their rheumatoid arthritis. Study medication will be given for eight weeks followed by a 4 week period during which the dose of study medication will be gradually reduced. The efficacy of the study medications will be determined by assessing severity of the rheumatoid arthritis during the study and safety will be determined by adverse event reporting, laboratory tests and biomarker analysis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PF-04171327 1 mg QD

Group Type EXPERIMENTAL

PF-04171327

Intervention Type DRUG

1 mg tablet once daily (QD) for 8 weeks

PF-04171327 5 mg QD

Group Type EXPERIMENTAL

PF-04171327

Intervention Type DRUG

5 mg tablet once daily (QD) for 8 weeks

PF-04171327 10 mg QD

Group Type EXPERIMENTAL

PF-04171327

Intervention Type DRUG

10 mg tablet once daily (QD) for 8 weeks

PF-04171327 15 mg QD

Group Type EXPERIMENTAL

PF-04171327

Intervention Type DRUG

15 mg tablet once daily (QD) for 8 weeks

prednisone 5 mg QD

Group Type ACTIVE_COMPARATOR

prednisone

Intervention Type DRUG

5 mg capsule once daily for 8 weeks

prednisone 10 mg QD

Group Type ACTIVE_COMPARATOR

prednisone

Intervention Type OTHER

10 mg capsule once daily for 8 weeks

placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type OTHER

placebo (tablet or capsule) once daily (QD) for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-04171327

1 mg tablet once daily (QD) for 8 weeks

Intervention Type DRUG

PF-04171327

5 mg tablet once daily (QD) for 8 weeks

Intervention Type DRUG

PF-04171327

10 mg tablet once daily (QD) for 8 weeks

Intervention Type DRUG

PF-04171327

15 mg tablet once daily (QD) for 8 weeks

Intervention Type DRUG

prednisone

5 mg capsule once daily for 8 weeks

Intervention Type DRUG

prednisone

10 mg capsule once daily for 8 weeks

Intervention Type OTHER

placebo

placebo (tablet or capsule) once daily (QD) for 8 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have documented rheumatoid arthritis with a duration of at least 3 months as determined by the investigator using standardly accepted criteria, must have been receiving methotrexate for at least 3 months to treat their rheumatoid arthritis, and must be free of any signs or symptoms of infection.

Exclusion Criteria

* Subjects cannot enter the study if they have recently received treatment with certain medications which might interfere with study medications;
* subjects cannot enter if they have abnormalities in certain blood tests, history of cancer, recent bone fracture or other significant conditions.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Catalina Pointe Clinical Research, Inc.

Tucson, Arizona, United States

Site Status

C. Michael Neuwelt, MD, Inc.

San Leandro, California, United States

Site Status

Javed Rheumatology Associates, Inc.

Newark, Delaware, United States

Site Status

Allergy, Asthma, Arthritis, and Lung Center

Daytona Beach, Florida, United States

Site Status

Millennium Research

Ormond Beach, Florida, United States

Site Status

Alastair C. Kennedy, MD

Vero Beach, Florida, United States

Site Status

The Center for Arthritis and Rheumatism

Vero Beach, Florida, United States

Site Status

Arthritis and Osteoporosis Medical Associates, PLLC

Brooklyn, New York, United States

Site Status

Cincinnati Rheumatic Disease Study Group, Inc.

Cincinnati, Ohio, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Low Country Rheumatology, PA

Charleston, South Carolina, United States

Site Status

Tricounty Radiology

Charleston, South Carolina, United States

Site Status

Accurate Clinical Research, Inc.

Houston, Texas, United States

Site Status

Arthritis Northwest, PLLC

Spokane, Washington, United States

Site Status

Revmatologichen kabinet, DKTs Sv. Pantaleimon OOD

Pleven, , Bulgaria

Site Status

Revmatologichno Otdelenie, MBAL - Plovdiv

Plovdiv, , Bulgaria

Site Status

MBAL "Sveti Ivan Rilski" Sofia; Klinika po Revmatologia

Sofia, , Bulgaria

Site Status

MBAL Sveti Ivan Rilski Sofia; Klinika po Revmatologia

Sofia, , Bulgaria

Site Status

Hospital Pablo Tobon Uribe

Medellín, Antioquia, Colombia

Site Status

Reumalab S.A.S

Medellín, Antioquia, Colombia

Site Status

Centro Integral de Reumatologia e Inmunologia CIREI

Bogota, Cundinamarca, Colombia

Site Status

Preventive Care SAS

Chía, Cundinamarca, Colombia

Site Status

Revmatologie Bruntal, S.R.O.

Bruntál, , Czechia

Site Status

Revmatologicka ambulance

Ostrava - Poruba, , Czechia

Site Status

Revmatologicka ambulance

Prague, , Czechia

Site Status

Thomayerova nemocnice

Prague, , Czechia

Site Status

Charite Universitaetsmedizin Berlin, Klinik fuer Rheumatologie

Berlin, , Germany

Site Status

Klinische Forschung Berlin-Buch GmbH

Berlin, , Germany

Site Status

CIRI GmbH

Frankfurt am Main, , Germany

Site Status

Dr. Rethy Pal Korhaz es Rendelointezet, II. Reumatologia Szakrendeles

Békéscsaba, , Hungary

Site Status

Budai Irgalmasrendi Korhaz, Reumatologia I.

Budapest, , Hungary

Site Status

Revita Reumatologiai Rendelo

Budapest, , Hungary

Site Status

Qualiclinic Kft.

Budapest, , Hungary

Site Status

Fejer Megyei Szent Gyorgy Korhaz Reumatologia

Székesfehérvár, , Hungary

Site Status

MAV Korhaz es Rendelointezet, Reumatologiai szakrendeles

Szolnok, , Hungary

Site Status

Krishna Institute of Medical Sciences Ltd

Secunderabad, Andhra Pradesh, India

Site Status

Shirdi Sai Hospital

Bangalore, Karnataka, India

Site Status

Dapartment of Rheumatology

Lucknow, Uttar Pradesh, India

Site Status

Hospital Raja Permaisuri Bainun

Ipoh, Perak, Malaysia

Site Status

Sunway Medical Centre

Petaling Jaya, Selangor, Malaysia

Site Status

Centro de Estudios de Investigacion Basica y Clinica SC.

Guadalajara, Jalisco, Mexico

Site Status

Unidad de Investigacion Biomedica del CEM

Mérida, Yucatán, Mexico

Site Status

Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.

San Luis Potosí City, , Mexico

Site Status

Centrum Kliniczno-Badawcze J. Brzezicki, B. Górniakiewicz-Brzezicka Lekarze Spółka Partnerska

Elblag, , Poland

Site Status

Nzoz "Lecznica Mak-Med S.C."

Nadarzyn, , Poland

Site Status

Wojewodzki Zespol Reumatologiczny im. dr J. Titz-Kosko

Sopot, , Poland

Site Status

Spitalul Clinic "Sfanta Maria", Clinica de Medicina Interna si Reumatologie

Bucharest, , Romania

Site Status

Spitalul Clinic Judetean de Urgenta "Sfantul Apostol Andrei"

Galati, , Romania

Site Status

Spitalul Clinic de Recuperare

Iași, , Romania

Site Status

Spitalul Clinic Judetean de Urgenta Targu Mures, Reumatologic

Tg Mures, , Romania

Site Status

GBOU VPO "Orenburg State Medical Academy of Ministry of Healthcare of Russian Federation"

Orenburg, Russian Federation, Russia

Site Status

Territorial Clinical Hospital

Barnaul, , Russia

Site Status

GBUZ of Kemerovo region Regional clinical hospital for was veterans

Kemerovo, , Russia

Site Status

Kemerovo Regional Clinical Hospital

Kemerovo, , Russia

Site Status

FSBI Scientific - Research Institute of Rheumatology RAMS n.a. V.A. Nasonova.

Moscow, , Russia

Site Status

LLC Consultative and Diagnostic Rheumatological Center Healthy Joints

Novosibirsk, , Russia

Site Status

Republican Hospital V.A.Baranov

Petrozavodsk, , Russia

Site Status

Ryazan Regional Clinical Cardiological Dispensary

Ryazan, , Russia

Site Status

Clinical Rheumatological Hospital #25

Saint Petersburg, , Russia

Site Status

Clinical Hospital #122 L.G. Sokolov

Saint Petersburg, , Russia

Site Status

MUZ City Clinical Hospital #12

Saratov, , Russia

Site Status

Smolensk Regional Clinical Hospital

Smolensk, , Russia

Site Status

Tomsk Regional Clinical Hospital

Tomsk, , Russia

Site Status

Vladimir Regional Clinical Hospital

Vladimir, , Russia

Site Status

Clinical Hospital of Emergency Care N.V. Soloviev

Yaroslavl, , Russia

Site Status

Yaroslavl Regional Clinical Hospital

Yaroslavl, , Russia

Site Status

Sverdlovsk Regional Clinical Hospital # 1

Yekaterinburg, , Russia

Site Status

Municilap Institution Central Clinical Hospital 6

Yekaterinburg, , Russia

Site Status

Institute of Rheumatology

Belgrade, , Serbia

Site Status

Institute for treatment and rehabilitation Niska Banja

Niška Banja, , Serbia

Site Status

AAGS, s.r.o. , nestatne zdravotnicke zariadenie

Dunajská Streda, , Slovakia

Site Status

Nestatna reumatologicka ambulancia

Považská Bystrica, , Slovakia

Site Status

Reumatologicka ambulancia, REUMEX, s.r.o.

Rimavská Sobota, , Slovakia

Site Status

Reumaglobal s.r.o.

Trnava, , Slovakia

Site Status

Nestatna reumatologicka ambulancia

Žilina, , Slovakia

Site Status

Panorama Medical Centre

Panorama, Cape Town, South Africa

Site Status

Emmed Research

Pretoria, Gauteng, South Africa

Site Status

KyungHee University Hospital

Seoul, Korea, South Korea

Site Status

Daegu Catholic University Medical Center, Department of Rheumatology

Daegu, , South Korea

Site Status

Inha University Hospital, Medicine/Rheumatology

Incheon, , South Korea

Site Status

Seoul National University Hospital, Rheumatology, Internal Medicine

Seoul, , South Korea

Site Status

Konkuk University Medical Center, Department of Rheumatology

Seoul, , South Korea

Site Status

Complejo Hospitalario Universitario A Coruña. Hospital Materno Infantil Teresa Herrera

A Coruña, , Spain

Site Status

Hospital SANITAS CIMA.

Barcelona, , Spain

Site Status

Municipal Medical Institution "City Clinical Hospital #3"

Chernivtsi, , Ukraine

Site Status

Municipal Medicoprophylactic Institution "Donetsk City Clinical Hospital #5".

Donetsk, , Ukraine

Site Status

National Scientific Centre "Institute of Cardiology n.a. M.D. Strazheska of NAMS of Ukraine".

Kiev, , Ukraine

Site Status

Komunalnyi zaklad Kyivskoi oblasnoi rady "Kyivska oblasna klinichna likarnia"

Kyiv, , Ukraine

Site Status

Komunalnyi zaklad Lvivskoi oblasnoi rady "Lvivskyi oblasnyi klinichnyi diahnostychnyi tsentr"

Lviv, , Ukraine

Site Status

Komunalna ustanova "Odeska oblasna klinichna likarnia"

Odesa, , Ukraine

Site Status

Municipal Establishment "City Clinical Hospital #9 n.a. O.I. Minakov", Department of Rheumatology

Odesa, , Ukraine

Site Status

Vinnytsya regional clinical hospital named after M.I. Pyrogova; Department of rheumatology

Vinnytsia, , Ukraine

Site Status

Municipal Institution:"Zaporizhzhya Regional Clinical Hospital",Rheumatology Dep.

Zaporizhzhya, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Colombia Czechia Germany Hungary India Malaysia Mexico Poland Romania Russia Serbia Slovakia South Africa South Korea Spain Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Buttgereit F, Strand V, Lee EB, Simon-Campos A, McCabe D, Genet A, Tammara B, Rojo R, Hey-Hadavi J. Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. RMD Open. 2019 Apr 16;5(1):e000889. doi: 10.1136/rmdopen-2018-000889. eCollection 2019.

Reference Type DERIVED
PMID: 31168411 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-023782-22

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

A9391010

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.